We examined uptake of the model therapeutic agent, minoxidil, into appendages, stratum corneum (SC), and through human skin, under the influence of different vehicles. Quantitative estimation of therapeutic drug deposition into all three areas has not previously been reported. Finite doses of minoxidil (2%, w/v) in formulations containing varying amounts of ethanol, propylene glycol (PG), and water (60:20:20, 80:20:0, and 0:80:20 by volume, respectively) were used. Minoxidil in SC (by tape stripping), appendages (by cyanoacrylate casting), and receptor fluid was determined by liquid scintillation counting. At early times (30 min, 2 h), ethanol-containing formulations (60:20:20 and 80:20:0) caused significantly greater minoxidil retention in SC and appendages, compared to the formulation lacking ethanol (0:80:20). A significant increase in minoxidil receptor penetration occurred with the PG-rich 0:80:20 formulation after 12 h. We showed that deposition of minoxidil into appendages, SC, and skin penetration into receptor fluid were similar in magnitude. Transport by the appendageal route is likely to be a key determinant of hair growth promotion by minoxidil.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/jps.21856 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Comparative Effects of Monotherapy with Topical Minoxidil, Oral Finasteride, and Topical Finasteride in Postmenopausal Women with Pattern Hair Loss: A Retrospective Cohort Study.
Skin Appendage Disord
August 2024
Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Introduction: Oral finasteride and topical minoxidil are long-standing androgenetic alopecia (AGA) treatments; topical finasteride is a more recent medicine. Few studies have compared their therapeutic effects in postmenopausal women. We compared the therapeutic impact of topical finasteride (1-4 sprays of 0.
View Article and Find Full Text PDFAndrogenetic Alopecia in Children and Adolescents: From Trichoscopy to Therapy.
Skin Appendage Disord
April 2024
Professor of Dermatology, University of Guadalajara, Guadalajara, Mexico.
Introduction: Pediatric androgenetic alopecia is a product of hormonal and genetic factors. The diagnosis depends on recognizing the hair loss pattern in the context of a positive family history and a typical trichoscopy.
Methods: A multicenter retrospective study assessing medical data from January 2008 to January 2023 of two reference centers - one public and one private in west Mexico.
Low-Dose Oral Minoxidil for Alopecia: A Comprehensive Review.
Skin Appendage Disord
December 2023
Philip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, FL, USA.
Article Synopsis
- Low-dose oral minoxidil (LDOM) shows good safety and effectiveness for treating hair loss conditions like male androgenetic alopecia (AGA) and female-pattern hair loss (FPHL), but it hasn’t received FDA approval yet.
- The typical starting dose is 1-5 mg/day for males and 0.5-1 mg/day for females, with a max dose of 5 mg/day; patients can increase doses if they respond well without significant side effects.
- Common side effects include unwanted hair growth and cardiovascular issues, with women being more susceptible to unwanted hair growth; LDOM's ability to treat hair loss may provide a new option for patients given the limited existing therapies.*
Increased Interest in Oral Minoxidil for Hair Loss Treatment Following Publication of August 2022 New York Times Article: A Google Trends Analysis.
Skin Appendage Disord
February 2024
Department of Dermatology, Weill Cornell Medicine, New York, NY, USA.
Article Synopsis
- - The study investigates the impact of a New York Times article on public interest in oral minoxidil, an off-label treatment for androgenetic alopecia (AGA), given its prevalence and negative effects on quality of life.
- - A cross-sectional analysis using Google Trends showed a notable rise in searches for "oral minoxidil" and "minoxidil" following the article's publication, indicating heightened public interest in hair loss treatments.
- - The results suggest a significant, ongoing increase in inquiries about oral minoxidil post-article, highlighting the need for larger clinical trials to better inform dermatologists and provide evidence-based treatment for AGA.
Relative Effects of Minoxidil 5%, Platelet-Rich Plasma, and Microneedling in Pattern Hair Loss: A Systematic Review and Network Meta-Analysis.
Skin Appendage Disord
December 2023
Mediprobe Research Inc., London, ON, Canada.
Background: Combination treatments may improve the utility of approved agents for the treatment of pattern hair loss (PHL); however, head-to-head comparisons are lacking.
Objective: The aim of the study was to compare the efficacy of 5% minoxidil, platelet-rich plasma (PRP), and microneedling across adults with PHL insofar as change in total hair density at 24 weeks.
Methods: We conducted a literature search in July 2022.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!